keyword
MENU ▼
Read by QxMD icon Read
search

Nab paclitaxel

keyword
https://www.readbyqxmd.com/read/29910636/performance-status-dynamics-during-treatment-with-nab-paclitaxel-plus-gemcitabine-versus-gemcitabine-alone-for-metastatic-pancreatic-cancer
#1
E Gabriela Chiorean, Daniel Von Hoff, Yin Wan, Sandra Margunato-Debay, Marc Botteman, David Goldstein
Objectives: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient's well-being during treatment with nab -paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial. Participants and methods: Descriptive analyses were performed for KPS at three time points (3 and 6 months after randomization and 1 month before disease progression) and for time to any KPS deterioration...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29903552/quality-adjusted-outcomes-stratified-by-response-in-patients-with-advanced-non-small-cell-lung-cancer-receiving-first-line-nab-paclitaxel-carboplatin-or-paclitaxel-carboplatin
#2
Vera Hirsh, Yin Wan, Fang-Ju Lin, Sandra Margunato-Debay, Teng Jin Ong, Marc Botteman, Corey Langer
BACKGROUND: First-line nab-paclitaxel/carboplatin was associated with a significantly improved overall response rate (primary endpoint) versus paclitaxel/carboplatin in a phase III trial of advanced non-small-cell lung cancer (NSCLC). We report the results of an analysis evaluating the correlation of response and the time to response with survival and quality-adjusted outcomes. PATIENTS AND METHODS: Using a landmark approach, progression-free survival (PFS), overall survival (OS), and quality-adjusted time without symptoms or toxicity (Q-TWiST) were compared between patients with a confirmed partial or complete response at or before 6 weeks (≤ 6-week responders) and those without (≤ 6-week nonresponders)...
May 7, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29902349/nab-paclitaxel-interrupt-cancer-stromal-interaction-through-cxcl10-mediated-il-6-down-regulation-in-vitro
#3
Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Syuichi Iwahashi, Yu Saito, Mitsuo Shimada
Cancer-associated fibroblasts (CAFs), which derived from cancer tissues stroma, interact with cancer cells and play an important role in cancer initiation, growth and metastasis. Nab-paclitaxel (nab-PTX) is the 130nm albumin binding paclitaxel and recommended for many kinds of cancer chemotherapy. It has been reported that nab-PTX stromal disrupting effect during pancreatic cancer treatment. The aim of this study is to illustrate the role of nab-PTX in cancer cells and CAFs interaction. The cancer cells (Mia paca2 and Panc-1) were co-cultured with CAFs or treat with CAFs conditioned medium, then their migration and invasion ability, epithelial-mesenchymal transition (EMT) related markers expression and CXCL10 expression and secretion were detected...
June 14, 2018: Cancer Science
https://www.readbyqxmd.com/read/29898269/metastatic-pancreatic-ductal-adenocarcinoma-diagnosis-and-treatment-with-a-view-to-the-future
#4
Adrian M J Pokorny, Venessa T Chin, Adnan M Nagrial, Desmond Yip, Lorraine A Chantrill
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental...
June 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29896283/from-first-line-to-sequential-treatment-in-the-management-of-metastatic-pancreatic-cancer
#5
REVIEW
Andrés Muñoz Martín, Manuel Hidalgo, Rafael Alvarez, Virginia Arrazubi, Joaquina Martínez-Galán, Mercedes Salgado, Teresa Macarulla, Alfredo Carrato
The current management of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) is based on systemic chemotherapy. The results of the MPACT and PRODIGE clinical trials have demonstrated that the combination of nab-paclitaxel and gemcitabine (GEM) as well as FOLFIRINOX regimen result in improvement in overall survival when compared to GEM alone. Treatment guidelines now recommend either one of these two regimens as first line treatment for fit patients with mPDAC. Because no head-to-head comparison between the two regimens exists, the selection of one versus the other is based on clinical criteria...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29882102/low-dose-continuous-5-fluorouracil-combined-with-leucovorin-nab-paclitaxel-oxaliplatin-and-bevacizumab-for-patients-with-advanced-pancreatic-cancer-a-retrospective-analysis
#6
William H Isacoff, Howard A Reber, Rudolph Bedford, William Hoos, Lola Rahib, Alexander Upfill-Brown, Timothy Donahue, O Joe Hines
BACKGROUND: Continuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer. As a protracted low-dose infusion, 5FU is antiangiogenic, and has synergy with bevacizumab. As shown in the treatment of breast cancer, bevacizumab and nab-paclitaxel are also synergetic. OBJECTIVE: In this paper we retrospectively analyze the survival of 65 patients with advanced pancreatic cancer who were treated with low-dose continuous (metronomic) chemotherapy given in conjunction with conventional anti-VEGF therapy...
June 7, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29879283/safety-and-efficacy-of-panitumumab-plus-neoadjuvant-chemotherapy-in-patients-with-primary-her2-negative-inflammatory-breast-cancer
#7
Naoko Matsuda, Xiaoping Wang, Bora Lim, Savitri Krishnamurthy, Ricardo H Alvarez, Jie S Willey, Charla A Parker, Juhee Song, Yu Shen, Jianhua Hu, Wenhui Wu, Nan Li, Gildy V Babiera, James L Murray, Banu K Arun, Abenaa M Brewster, James M Reuben, Michael C Stauder, Chad M Barnett, Wendy A Woodward, H T Carisa Le-Petross, Anthony Lucci, Sarah M DeSnyder, Debu Tripathy, Vicente Valero, Naoto T Ueno
Importance: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in patients with IBC. Objective: To evaluate the safety and efficacy of the anti-EGFR antibody panitumumab plus neoadjuvant chemotherapy in patients with primary human epidermal growth factor receptor 2 (HER2)-negative IBC...
June 7, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29878040/nab-paclitaxel-plus-carboplatin-or-gemcitabine-vs-gemcitabine-plus-carboplatin-as-first-line-treatment-for-patients-with-triple-negative-metastatic-breast-cancer-results-from-the-tnacity-trial
#8
D A Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, R Young, C Bengala, H Ali, J Eakel, A Schneeweiss, L de la Cruz-Merino, S Wilks, J O'Shaughnessy, S Glück, H Li, J Miller, D Barton, N Harbeck
Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and/safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC. Patients and methods: Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1:1:1) nab-P 125 mg/m2 plus C AUC 2, nab-P 125 mg/m2 plus G 1000 mg/m2, or G 1000 mg/m2 plus C AUC 2, all on days 1, 8 q3w...
June 6, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29872267/nab-paclitaxel-carboplatin-in-elderly-patients-with-advanced-squamous-non-small-cell-lung-cancer-a-retrospective-analysis-of-a-phase-iii-trial
#9
Cesare Gridelli, Tianlei Chen, Amy Ko, Mary E O'Brien, Teng Jin Ong, Mark A Socinski, Pieter E Postmus
Background: Limited data on elderly patients with squamous advanced non-small cell lung cancer (NSCLC) preclude optimal treatment. Here, we report the outcomes of a retrospective analysis of a subset of patients ≥70 years with squamous histology from the Phase III trial that evaluated nab-paclitaxel/carboplatin vs paclitaxel/carboplatin. Patients and methods: Patients with stage IIIB/IV NSCLC received (1:1) nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 or paclitaxel 200 mg/m2 on day 1, both with carboplatin area under the curve 6 mg×min/mL on day 1 every 3 weeks...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29868007/pancreatic-ductal-adenocarcinoma-a-strong-imbalance-of-good-and-bad-immunological-cops-in-the-tumor-microenvironment
#10
REVIEW
Etienne D Foucher, Clément Ghigo, Salem Chouaib, Jérôme Galon, Juan Iovanna, Daniel Olive
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers with very few available treatments. For many decades, gemcitabine was the only treatment for patients with PDAC. A recent attempt to improve patient survival by combining this chemotherapy with FOLFIRINOX and nab-paclitaxel failed and instead resulted in increased toxicity. Novel therapies are urgently required to improve PDAC patient survival. New treatments in other cancers such as melanoma, non-small-cell lung cancer, and renal cancer have emerged, based on immunotherapy targeting the immune checkpoints cytotoxic T-lymphocyte-associated antigen 4 or programmed death 1 ligand...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29862232/breakthroughs-in-the-treatment-of-advanced-squamous-cell-nsclc-not-the-neglected-sibling-anymore
#11
REVIEW
Georgios Tsironis, Dimitrios C Ziogas, Anastasios Kyriazoglou, Marita Lykka, Konstantinos Koutsoukos, Aristotelis Bamias, Meletios-Athanasios Dimopoulos
During the last years, translational research has contributed in many advances in the treatment of non-small cell lung cancer (NSCLC) discovering genetic alternations or recognizing the immuno-escape and neo-angiogenesis of lung cancer. Although the majority of these advances took place in the non-squamous histological subtype, therapeutic options for patients diagnosed with advanced squamous cell lung cancer (SqCLC) have been also enriched significantly with the addition of nab-paclitaxel in the conventional chemotherapy; the introduction of necitumumab, afatinib and erlotinib in the inhibition of epidermal growth factor receptor (EGFR) axis and of ramucirumab in the inhibition of VEGF-induced angiogenesis and last with the approvals of nivolumab, pembrolizumab atezolizumab and durvalumab soon in the promising field of immunotherapies...
April 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29861395/a-randomized-phase-iii-study-comparing-carboplatin-with-nab-paclitaxel-versus-docetaxel-for-elderly-patients-with-squamous-cell-lung-cancer-study-protocol
#12
Yoshihito Kogure, Hideo Saka, Yuichi Takiguchi, Shinji Atagi, Takayasu Kurata, Noriyuki Ebi, Akira Inoue, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Akiko Kada, Takeharu Yamanaka, Masahiko Ando, Nobuyuki Yamamoto, Akihiko Gemma, Yukito Ichinose
BACKGROUND: Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older...
May 19, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29850322/-gnq-209p-mutation-in-metastatic-uveal-melanoma-and-treatment-outcome
#13
Nagla Abdel Karim, Ihab Eldessouki, Ahmad Taftaf, Deeb Ayham, Ola Gaber, Abouelmagd Makramalla, Zelia M Correa
Metastatic prognosis in uveal melanoma is assessed by gene expression profiling (GEP) testing of the tumor cells, usually obtained by fine needle aspiration (FNA). GEP has demonstrated high accuracy in distinguishing class I and II tumors, both having different metastatic potential. Transcriptomic studies identified distinct mutations including somatic mutations in GNAQ and GNA11 , detected in more than 80%, and contribute to the upregulation of the mitogen-activated protein kinase (MAPK) pathway and the development of uveal melanoma (UM)...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29846848/nab-paclitaxel-maintenance-therapy-following-carboplatin-nab-paclitaxel-combination-therapy-in-chemotherapy-na%C3%A3-ve-patients-with-advanced-non-small-cell-lung-cancer-multicenter-open-label-single-arm-phase-ii-trial
#14
Akira Nakao, Junji Uchino, Fumiyasu Igata, Rintaro On, Takato Ikeda, Hiroshi Yatsugi, Ryosuke Hirano, Tomoya Sasaki, Keiko Tanimura, Tatsuya Imabayashi, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Nobuhiko Nagata, Kentaro Watanabe, Junji Kishimoto, Koichi Takayama, Masaki Fujita
Background A global multicenter study demonstrated superiority of carboplatin + nab-paclitaxel (PTX) therapy compared to carboplatin + PTX in terms of response rate (RR) and non-inferiority in terms of progression free survival (PFS) and overall survival (OS) in untreated patients with stage IIIB/IV non-small cell lung cancer; no clinical findings have so far been reported on maintenance therapies with nab-PTX. The aim of this study was to determine the efficacy and safety of maintenance therapy with nab-PTX following carboplatin + nab-PTX combination therapy...
May 30, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29846765/gemcitabine-plus-nab-paclitaxel-vs-folfirinox-for-patients-with-advanced-pancreatic-cancer
#15
Junko Tahara, Kyoko Shimizu, Nao Otsuka, Junichi Akao, Yukiko Takayama, Katsutoshi Tokushige
PURPOSE: New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. METHODS: Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital...
May 30, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29804945/total-pancreatoduodenectomy-en-bloc-with-superior-mesenteric-artery-and-vein-resection-after-gemcitabine-and-nab-paclitaxel-neoadjuvancy
#16
E Vicente, Y Quijano, B Ielpo, H Duran
BACKGROUND: Pancreatectomy for locally advanced adenocarcinoma affecting the superior mesenteric artery (SMA) and superior mesenteric vein (SMV) is still under discussion [1]. However, in selected cases, in light of the advancement of recent neoadjuvant treatments, it must be taken into account [2,3]. This video demonstrates some of the technical aspects of SMA and SMV resection as well as some tips of vascular reconstruction. METHODS: A 48-year-old man with a large adenocarcinoma of the uncinated process affecting the SMA and SMV underwent 3 cycles of gemcitabine and nab-paclitaxel neoadjuvancy...
September 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29799479/a-phase-ii-study-of-pelareorep-reolysin-%C3%A2-in-combination-with-gemcitabine-for-patients-with-advanced-pancreatic-adenocarcinoma
#17
Devalingam Mahalingam, Sanjay Goel, Santiago Aparo, Sukeshi Patel Arora, Nicole Noronha, Hue Tran, Romit Chakrabarty, Giovanni Selvaggi, Andres Gutierrez, Matthew Coffey, Steffan T Nawrocki, Gerard Nuovo, Monica M Mita
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone. Pelareorep (REOLYSIN® ), a proprietary isolate of reovirus Type 3 Dearing, has shown antitumor activity in clinical and preclinical models. In addition to direct cytotoxic effects, pelareorep can trigger antitumor immune responses...
May 25, 2018: Cancers
https://www.readbyqxmd.com/read/29791286/metastatic-pancreatic-cancer-asco-clinical-practice-guideline-update
#18
Davendra P S Sohal, Erin B Kennedy, Alok Khorana, Mehmet S Copur, Christopher H Crane, Ignacio Garrido-Laguna, Smitha Krishnamurthi, Cassadie Moravek, Eileen M O'Reilly, Philip A Philip, Ramesh K Ramanathan, Joseph T Ruggiero, Manish A Shah, Susan Urba, Hope E Uronis, Michelle W Lau, Daniel Laheru
Purpose In 2016, ASCO published a guideline to assist in clinical decision making in metastatic pancreatic cancer for initial assessment after diagnosis, first- and second-line treatment options, palliative and supportive care, and follow-up. The purpose of this update is to incorporate new evidence related to second-line therapy for patients who have experienced disease progression or intolerable toxicity during first-line therapy. Methods ASCO convened an Expert Panel to conduct a systematic review of the literature on second-line therapy published between June 2015 and January 2018...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29770997/gemcitabine-nab-paclitaxel-for-pediatric-relapsed-refractory-sarcomas
#19
Jonathan L Metts, Adina L Alazraki, Dana Clark, Ernest K Amankwah, Karen J Wasilewski-Masker, Bradley A George, Thomas A Olson, Thomas Cash
BACKGROUND: Pediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab-paclitaxel in combination has not been reported in pediatrics. PROCEDURE: We reviewed the records of fifteen relapsed/refractory patients and one treatment-naïve patient who received gemcitabine/nab-paclitaxel at our institution...
May 17, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29765563/targeted-therapies-in-the-management-of-locally-advanced-and-metastatic-pancreatic-cancer-a-systematic-review
#20
REVIEW
Anjali V Sheahan, Andrew V Biankin, Christopher R Parish, Levon M Khachigian
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy...
April 20, 2018: Oncotarget
keyword
keyword
84689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"